

ASX RELEASE

7 February 2020

**Final Director's Interest Notice – Appendix 3Z: Andrew Cooke**

Appendix 3Z Final Director's Interest Notice for Andrew Cooke is attached.

This ASX announcement was approved and authorised for release by the Company Secretary of Amplia Therapeutics Limited.

- End -

**For Further Information**

Andrew J. Cooke  
Company Secretary  
[andrew@ampliatx.com](mailto:andrew@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

|                |                             |
|----------------|-----------------------------|
| Name of entity | Amplia Therapeutics Limited |
| ABN            | 16 165 160 841              |

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

|  |                   |
|--|-------------------|
| Name of director                         | Andrew John Cooke |
| Date of last notice                      | 5 August 2019     |
| Date that director ceased to be director | 6 February 2020   |

### Part 1 – Director's relevant interests in securities of which the director is the registered holder *In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |
|--|
| <b>Number &amp; class of securities</b><br><br>375 Fully Paid Ordinary Shares<br>480,000 Options Exercise Price A\$0.60 Expiry Date 31 August 2023<br>63 Options Exercise Price A\$0.15 Expiry Date 30 June 2022 |
|--|

+ See chapter 19 for defined terms.

## Appendix 3Z Final Director's Interest Notice

---

### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

| Name of holder & nature of interest<br>Note: Provide details of the circumstances giving rise to the relevant interest | Number & class of securities |
|--|------------------------------|
|  |                              |

### Part 3 – Director's interests in contracts

|   |  |
|---|--|
| Detail of contract                                    |  |
| Nature of interest                                    |  |
| Name of registered holder<br>(if issued securities)   |  |
| No. and class of securities to which interest relates |  |

7 February 2020

---

+ See chapter 19 for defined terms.